N/A
Completed N=51
Clinical Study for Workflow and Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System for Treating Symptomatic Paroxysmal AF (QDOT-Micro)
Source: ClinicalTrials.gov NCT02944968 ↗Enrolled (actual)
51
Serious AEs
14.0%
Results posted
Nov 2019
Primary outcomePrimary: Number of Participants With Entrance Block Confirmation in the Total Effectiveness Outcome Population — 46; 1 Participants
Summary
The QDOT-Micro study is a prospective, multi-center, non-randomized, interventional clinical study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Entrance Block Confirmation in the Total Effectiveness Outcome Population |
46; 1 | — |
| SECONDARY Number of Participants With Early Onset Primary Adverse Events in Total Safety Population |
1; 1; 1; 47 | — |
Eligibility Criteria
Inclusion Criteria
Candidates for this study must meet ALL of the following criteria:
- Age 18 or older
- Patients who have signed the Patient Informed Consent Form (ICF)
- Subjects diagnosed with symptomatic documented PAF* who are candidates for catheter ablation
- Able and willing to comply with all pre-, post-, and follow-up testing and requirements (eg. Patient not confined by a court ruling)
Exclusion Criteria
Candidates for this study will be EXCLUDED from the study if ANY of the following conditions apply:
- Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
- Previous ablation for atrial fibrillation.
- Previously diagnosed with persistent AF.
- Documented Left Atrial thrombus
- Any carotid stenting or endarterectomy
- LA size >50mm
- LVEF <40%
- Uncontrolled heart failure or NYHA function class III and IV
- History of blood clotting or bleeding abnormalities or contraindication to anticoagulation ( heparin, warfarin, or dabigatran)
- History of a documented thromboembolic event (including TIA) within the past 12 months.
- Previous PCI/MI within the past 3 months
- Previous cardiac surgery (e.g CABG) in conjunction with valve surgery or any valvular cardiac surgical/percutaneous procedure (e.g ventriculotomy, atriomy, valve repair or replacement, presence of a prosthetic valve) within the past 6 months.
- Awaiting cardiac transplantation or other cardiac surgery within the next 6 months.
- Unstable angina
- Significant pulmonary disease (eg, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
- Acute illness, active systemic infection, or sepsis.
- Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation.
- Presence of a condition that precludes vascular access.
- Presence of implantable cardioverter-defibrillator (ICD)
- Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this trial.
- Currently enrolled in an investigational study evaluating another device, biologics, or drug.
- Women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the clinical investigation (as evidenced by pregnancy test if of child bearing potential).
- Life expectancy less than 12 months.
- Presenting contra-indication for the devices used in the study, as indicated in the respective instructions for use.
Data sourced from ClinicalTrials.gov (NCT02944968). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.